Response assessment in paediatric intracranial ependymoma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group.

[1]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[2]  T. Pietsch,et al.  Pediatric ependymoma: an overview of a complex disease , 2021, Child's Nervous System.

[3]  David T. W. Jones,et al.  Cross-species genomics reveals oncogenic dependencies in ZFTA/C11orf95 fusion-positive supratentorial ependymomas. , 2021, Cancer discovery.

[4]  S. Ballereau,et al.  ZFTA-translocations constitute ependymoma chromatin remodeling and transcription factors. , 2021, Cancer discovery.

[5]  D. Parsons,et al.  ZFTA-RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma. , 2021, Cancer discovery.

[6]  N. Foreman.  Long term outcomes from the second l'Associazione Italiana di Ematologia e Oncologia Pediatrica ( AIEOP) protocol. , 2021, Neuro-oncology.

[7]  U. Löbel,et al.  A Diagnostic Algorithm for Posterior Fossa Tumors in Children: A Validation Study , 2021, American Journal of Neuroradiology.

[8]  F. Andreiuolo,et al.  Supratentorial ependymoma in childhood: more than just RELA or YAP , 2021, Acta Neuropathologica.

[9]  D. Ellison,et al.  EPEN-54. ACNS0831, PHASE III RANDOMIZED TRIAL OF POST-RADIATION CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED EPENDYMOMA AGES 1 TO 21 YEARS , 2020, Neuro-Oncology.

[10]  S. Pfister,et al.  The AIEOP 2nd series of children and adolescents intracranial Ependymoma. An integrated molecular and clinical characterization with a long-term follow-up. , 2020, Neuro-oncology.

[11]  D. Indelicato,et al.  Surveillance imaging in pediatric ependymoma , 2020, Pediatric blood & cancer.

[12]  T. Jacques,et al.  A retrospective analysis of recurrent pediatric ependymoma reveals extremely poor survival and ineffectiveness of current treatments across central nervous system locations and molecular subgroups , 2020, Pediatric blood & cancer.

[13]  T. MacDonald,et al.  Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. , 2020, The Lancet. Oncology.

[14]  I. Pollack,et al.  Response assessment in diffuse intrinsic pontine glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. , 2020, The Lancet. Oncology.

[15]  K. Yeom,et al.  Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. , 2020, The Lancet. Oncology.

[16]  F. Andreiuolo,et al.  Ependymomas in infancy: underlying genetic alterations, histological features, and clinical outcome , 2020, Child's Nervous System.

[17]  J. Kirsch,et al.  Balanced Steady-State Free Precession Techniques Improve Detection of Residual Germ Cell Tumor for Treatment Planning , 2020, American Journal of Neuroradiology.

[18]  L. Klein-Hitpass,et al.  Improved risk-stratification for posterior fossa ependymoma of childhood considering clinical, histological and genetic features – a retrospective analysis of the HIT ependymoma trial cohort , 2019, Acta Neuropathologica Communications.

[19]  S. Mueller,et al.  A systematic review and meta-analysis of outcomes in pediatric, recurrent ependymoma , 2019, Journal of Neuro-Oncology.

[20]  T. Merchant,et al.  Molecular Grouping and Outcomes of Young Children with Newly Diagnosed Ependymoma Treated on the Multi-Institutional SJYC07 Trial. , 2019, Neuro-oncology.

[21]  M. Kool,et al.  Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series. , 2019, The oncologist.

[22]  T. Zhou,et al.  Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. Hawkins,et al.  Craniospinal irradiation as part of re-irradiation for children with recurrent intracranial ependymoma , 2018, Neuro-oncology.

[24]  C. Sommer,et al.  Childhood supratentorial ependymomas with YAP1‐MAMLD1 fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features , 2018, Brain pathology.

[25]  F. Tensaouti,et al.  Pediatric Localized Intracranial Ependymomas: A Multicenter Analysis of the Société Française de lutte contre les Cancers de l'Enfant (SFCE) from 2000 to 2013. , 2018, International journal of radiation oncology, biology, physics.

[26]  S. Bisdas,et al.  Differential diagnosis of posterior fossa tumours in children: new insights , 2018, Pediatric Radiology.

[27]  P. Ferroli,et al.  Pediatric intracranial ependymoma: correlating signs and symptoms at recurrence with outcome in the second prospective AIEOP protocol follow-up , 2018, Journal of Neuro-Oncology.

[28]  Martin Sill,et al.  Heterogeneity within the PF-EPN-B ependymoma subgroup , 2018, Acta Neuropathologica.

[29]  David T. W. Jones,et al.  Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas , 2018, Acta Neuropathologica.

[30]  G. Reifenberger,et al.  EANO guidelines for the diagnosis and treatment of ependymal tumors. , 2018, Neuro-oncology.

[31]  T. Merchant,et al.  Outcomes After Reirradiation for Recurrent Pediatric Intracranial Ependymoma. , 2018, International journal of radiation oncology, biology, physics.

[32]  Susan M. Chang,et al.  Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee , 2018, Neuro-oncology.

[33]  M. Snuderl,et al.  Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival , 2017, Journal of Neuro-Oncology.

[34]  T. Merchant.  Current Clinical Challenges in Childhood Ependymoma: A Focused Review. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  I. Izbudak,et al.  Supratentorial Tumors in Pediatric Patients. , 2017, Neuroimaging clinics of North America.

[36]  K. Aldape,et al.  The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants , 2016, Acta Neuropathologica.

[37]  P. Ferroli,et al.  Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma. , 2016, Neuro-oncology.

[38]  H. Heinzl,et al.  Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma , 2016, Acta neuropathologica communications.

[39]  T. Hortobágyi,et al.  Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  R. Gilbertson,et al.  Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma. , 2015, Neuro-oncology.

[41]  Marion Smits,et al.  Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. , 2015, Neuro-oncology.

[42]  Gary D Bader,et al.  Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. , 2015, Cancer cell.

[43]  F. Boop,et al.  Postoperative Intraspinal Subdural Collections after Pediatric Posterior Fossa Tumor Resection: Incidence, Imaging, and Clinical Features , 2015, American Journal of Neuroradiology.

[44]  F. Gilles,et al.  A retrospective analysis of recurrent intracranial ependymoma , 2014, Pediatric blood & cancer.

[45]  C. McPherson,et al.  Critical role of imaging in the neurosurgical and radiotherapeutic management of brain tumors. , 2014, Radiographics : a review publication of the Radiological Society of North America, Inc.

[46]  M. Prados,et al.  Challenges with defining response to antitumor agents in pediatric neuro‐oncology: A report from the response assessment in pediatric neuro‐oncology (RAPNO) working group , 2013, Pediatric blood & cancer.

[47]  C. Hawkins,et al.  Survival benefit for pediatric patients with recurrent ependymoma treated with reirradiation. , 2012, International journal of radiation oncology, biology, physics.

[48]  T. Merchant,et al.  Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas , 2012, Acta Neuropathologica.

[49]  J. Fangusaro,et al.  Evaluating the incidence and utility of microscopic metastatic dissemination as diagnosed by lumbar cerebro-spinal fluid (CSF) samples in children with newly diagnosed intracranial ependymoma , 2011, Journal of Neuro-Oncology.

[50]  J. Grill,et al.  Utility of Cerebrospinal Fluid Cytology in Newly Diagnosed Childhood Ependymoma , 2010, Journal of pediatric hematology/oncology.

[51]  P. Lichter,et al.  Molecular staging of intracranial ependymoma in children and adults. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  T. Merchant,et al.  Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. , 2009, The Lancet. Oncology.

[53]  U. de Girolami,et al.  Cerebrospinal fluid cytology in patients with ependymoma , 2008, Cancer.

[54]  T. Merchant,et al.  A retrospective study of surgery and reirradiation for recurrent ependymoma. , 2008, International journal of radiation oncology, biology, physics.

[55]  I. Pollack,et al.  Metastatic ependymoma: A multi‐institutional retrospective analysis of prognostic factors , 2008, Pediatric blood & cancer.

[56]  T. Merchant,et al.  CSF cytology has limited value in the evaluation of patients with ependymoma who have MRI evidence of metastasis , 2006, Pediatric blood & cancer.

[57]  P. Lichter,et al.  Identification of Gains on 1q and Epidermal Growth Factor Receptor Overexpression as Independent Prognostic Markers in Intracranial Ependymoma , 2006, Clinical Cancer Research.

[58]  P. Navarria,et al.  Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: final results of the first prospective AIEOP (Associazione Italiana di Ematologia-Oncologia Pediatrica) study. , 2004, International journal of radiation oncology, biology, physics.

[59]  L. Solymosi,et al.  Subdural enhancement on postoperative spinal MRI after resection of posterior cranial fossa tumours , 2004, Neuroradiology.

[60]  E. Bouffet,et al.  Chemotherapy for intracranial ependymomas , 1999, Child's Nervous System.

[61]  N. Stence,et al.  Fractionated stereotactic radiosurgery for recurrent ependymoma in children , 2013, Journal of Neuro-Oncology.

[62]  Concezio Di Rocco,et al.  Posterior Fossa Tumors , 1993, Principles of Pediatric Neurosurgery.